Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

2017-2018 Hematology Drug Approvals at the Food and Drug Administration (FDA): Communication of Patient-Reported Outcomes (PRO) Information in FDA Clinical Reviews and Prescribing Information (PI)

Janice Kim, PharmD, MSc, Bindu Kanapuru, MD, Jessica K Roydhouse, PhD MPH, Ann T. Farrell, MD, Najat Bouchkouj, MD, Hussein Ezzeldin, PhD, Paul Kluetz, MD

Blood (2019) 134 (Supplement_1): 3450.

https://doi.org/10.1182/blood-2019-125798

Published: 2019

Journal Articles

Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia

Chunfen Zhang, MD, Ritul Sharma, MSc., Thakur Satbir, PhD, Allison Cheney, Olena Vaske, PhD, Lauren Sanders, Jessica Boklan, MD, Victor A. Lewis, MD, Ronald Anderson, MDFRCPC, Olga Kovalchuk, MD, PhD, Norman J. Lacayo, MD, Aru Narendran, MD PhD, Kevin J. Bielamowicz, MD

Blood (2019) 134 (Supplement_1): 2633.

https://doi.org/10.1182/blood-2019-131444

Published: 2019

Journal Articles

Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)

Blood (2019) 134 (Supplement_1): 4455.

https://doi.org/10.1182/blood-2019-127480

Published: 2019

Journal Articles

Stratification of Responders and Non-Responders in the Reach-1 Trial Based on Serum Proteomic Analysis

Sherry Owens, PhD, Michael A. Pratta, MSc, Hao Liu, PhD, Michael C. Arbushites, Chuan Tian, PhD, Michael D. Howell, PhD

Blood (2019) 134 (Supplement_1): 4531.

https://doi.org/10.1182/blood-2019-127147

Published: 2019

Journal Articles

Novel Therapeutics That Can Target and Eradicate Leukemic Stem Cells in Acute Myeloid Leukemia: Investigating FDA-Approved Anti-Inflammatory Compounds

Isabella Iasenza, Meaghan Boileau, BSc, Andrea Neumann, BSc., Héloïse Frison, MSc., Mark D. Minden, MD PhD, Isabelle Laverdiere, BPharm, MSc, PhD, Kolja Eppert, MSc, PhD

Blood (2019) 134 (Supplement_1): 5052.

https://doi.org/10.1182/blood-2019-125338

Published: 2019

Journal Articles

The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes

Abhay Singh, MBBS, MPH, Sarah Sadek, MD, Mark G. Faber, DO, Jeffrey Baron, PharmD, James E. Thompson, MD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD, Swapna Thota, MD

Blood (2019) 134 (Supplement_1): 5095.

https://doi.org/10.1182/blood-2019-132040

Published: 2019

Journal Articles

Real World Use of IDH2- Targeted Inhibitors in a Single Academic Medical Center Experience Since Enasidenib FDA-Approval

Jordan Gales, MD, Matthew S. McKinney, MD, Harry P. Erba, MD PhD, Chad M. McCall, MD PhD

Blood (2019) 134 (Supplement_1): 5131.

https://doi.org/10.1182/blood-2019-125135

Published: 2019

Journal Articles

Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey

Maximilian Merz, Isabelle Vande Broek, MD PhD, Manuel Pérez, Dr., Brigitte Kolb, MD, Argiris Symeonidis, MD PhD, Emmanouil Nikolousis, Athanasios Zomas, Francisco Gonzalez, Lenka Kellermann, BS, MBA, Hartmut Goldschmidt

Blood (2019) 134 (Supplement_1): 3115.

https://doi.org/10.1182/blood-2019-122706

Published: 2019

Journal Articles

A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies

Jennifer A. Woyach, MD, Ian W. Flinn, MD PhD, Deborah M. Stephens, Farrukh T. Awan, MD MS, Kerry A. Rogers, MD, Sean D. Reiff, Ron E. Savage, Sudharshan Eathiraj, Lyndsey A. Szuszkiewicz, Kate Tith, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 3136.

https://doi.org/10.1182/blood-2018-99-116338

Published: 2018

Journal Articles

FOS Expression Distinguishes Two Groups of Atypical CML (aCML) Allowing Targeted Therapy

Manja Meggendorfer, PhD, Wencke Walter, PhD, Stephan Hutter, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2018) 132 (Supplement 1): 3893.

https://doi.org/10.1182/blood-2018-99-111832

Published: 2018

Journal Articles

Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide

Ayalew Tefferi, MD, Natasha Szuber, MD, Kebede H. Begna, MD, Mrinal M. Patnaik, MD MBBS, Michelle A. Elliott, MD, C. Christopher Hook, MD, Alexandra Wolanskyj, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS

Blood (2018) 132 (Supplement 1): 4287.

https://doi.org/10.1182/blood-2018-99-116601

Published: 2018

Journal Articles

Building Capacity for Relapsed/Refractory ALL Patients Needing CAR-T Cells: How Do We Prepare?

Roy Khalife, MD, Joshua Montroy, MSc, Wasithep Limvorapitak, MD, Raewyn Broady, MBChB, Dean Fergusson, PhD, Harold Atkins, MD, Robert Holt, PhD, Manoj Lalu, MD PhD FRCPC, Natasha Kekre, MD FRCPC

Blood (2018) 132 (Supplement 1): 5159.

https://doi.org/10.1182/blood-2018-99-116879

Published: 2018

Journal Articles

The Un-BLyS-Ful State: Blocking Factor VIII Inhibitor Development with BLyS Depletion

Bhavya S Doshi, MD, Robert J. Davidson, BS, Valder R Arruda, MD PhD

Blood (2018) 132 (Supplement 1): 138.

https://doi.org/10.1182/blood-2018-99-114795

Published: 2018

Journal Articles

Cost-Effectiveness Analyses of FDA-Approved Drugs for Cancer Indications, 2015-2017

Ohad Oren, MD

Blood (2018) 132 (Supplement 1): 5833.

https://doi.org/10.1182/blood-2018-99-109707

Published: 2018

Journal Articles

The Persistent Survival of MPN Cells to JAK2 Inhibition Is Dependent on SHP2 Activity, Which May Provide a Therapeutic Target to Enhance Current Anti-MPN Therapies

Garima Pandey, Guolin Zhang, Narmin Amin, Lucia Mazzacurati, Eric B. Haura, Gary W. Reuther, PhD

Blood (2018) 132 (Supplement 1): 3064.

https://doi.org/10.1182/blood-2018-99-118641

Published: 2018

Journal Articles

Real-World Testing and Treatment Patterns in Chronic Lymphocytic Leukemia (CLL) in the United States during the Modern Era: A SEER Patterns of Care Analysis

Erlene K. Seymour, MDBS, Julie J. Ruterbusch, M.P.H., Jennifer L. Beebe-Dimmer, PhD, M.P.H., Charles A. Schiffer, MD

Blood (2017) 130 (Supplement 1): 3384.

https://doi.org/10.1182/blood.V130.Suppl_1.3384.3384

Published: 2017

Journal Articles

Fulfillment of Postmarketing Commitments for Novel Malignant Hematology Products Granted Accelerated Approval By the FDA between 2011-2016

Marjorie E Zettler, PhD MPH, Chadi Nabhan, MD MBA, FACP

Blood (2017) 130 (Supplement 1): 4712.

https://doi.org/10.1182/blood.V130.Suppl_1.4712.4712

Published: 2017

Journal Articles

Felipe Samaniego

Neeraj Jain, PhD, Lalit Sehgal, PhD, R. Eric Davis, MD, Stephen Joseph Shuttleworth, PhD, Felipe Samaniego, MD

Blood (2016) 128 (22): 5145.

https://doi.org/10.1182/blood.V128.22.5145.5145

Published: 2016

Journal Articles

Extended Storage of Refrigerated Platelets in Isoplate and Intersol PAS: An Evaluation of Two FDA-Approved Methods of Collection

Kristin Reddoch, PhD, Robbie Montgomery, MS, Todd Getz, PhD, Andrew P Cap, MDPhD

Blood (2016) 128 (22): 2631.

https://doi.org/10.1182/blood.V128.22.2631.2631

Published: 2016

Journal Articles

Long Term Trends in Chronic Myeloid Leukemia (CML) Following the FDA Approval of Tyrosine Kinase Inhibitors (TKIs), on Bone Marrow Transplant Rates and Clinical Outcomes - a Study of the Nationwide Inpatient Sample Between 1998-2011

Parshva Patel, MD, Indumathy Varadarajan, MD, Gaurav Varma, MSPH, Trotta Christina, MD, Kristine Ward, MD, Maneesh Jain, MD, Michael Styler, MD

Blood (2015) 126 (23): 3300.

https://doi.org/10.1182/blood.V126.23.3300.3300

Published: 2015

NARROW

2017-2018 Hematology Drug Approvals at the Food and Drug Administration (FDA): Communication of Patient-Reported Outcomes (PRO) Information in FDA Clinical Reviews and Prescribing Information (PI)

Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia

Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)

Stratification of Responders and Non-Responders in the Reach-1 Trial Based on Serum Proteomic Analysis

Novel Therapeutics That Can Target and Eradicate Leukemic Stem Cells in Acute Myeloid Leukemia: Investigating FDA-Approved Anti-Inflammatory Compounds

The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes

Real World Use of IDH2- Targeted Inhibitors in a Single Academic Medical Center Experience Since Enasidenib FDA-Approval

Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey

A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies

FOS Expression Distinguishes Two Groups of Atypical CML (aCML) Allowing Targeted Therapy

Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide

Building Capacity for Relapsed/Refractory ALL Patients Needing CAR-T Cells: How Do We Prepare?

The Un-BLyS-Ful State: Blocking Factor VIII Inhibitor Development with BLyS Depletion

Cost-Effectiveness Analyses of FDA-Approved Drugs for Cancer Indications, 2015-2017

The Persistent Survival of MPN Cells to JAK2 Inhibition Is Dependent on SHP2 Activity, Which May Provide a Therapeutic Target to Enhance Current Anti-MPN Therapies

Real-World Testing and Treatment Patterns in Chronic Lymphocytic Leukemia (CLL) in the United States during the Modern Era: A SEER Patterns of Care Analysis

Fulfillment of Postmarketing Commitments for Novel Malignant Hematology Products Granted Accelerated Approval By the FDA between 2011-2016

Felipe Samaniego

Extended Storage of Refrigerated Platelets in Isoplate and Intersol PAS: An Evaluation of Two FDA-Approved Methods of Collection

Long Term Trends in Chronic Myeloid Leukemia (CML) Following the FDA Approval of Tyrosine Kinase Inhibitors (TKIs), on Bone Marrow Transplant Rates and Clinical Outcomes - a Study of the Nationwide Inpatient Sample Between 1998-2011

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only